In 2016, Kijanka et al. (147) reported a combination of optical conjugations based on two different Nbs against two different breast tumor markers, for an improved tumor detection: Nb B9 against CAIX, which targets the peri-necrotic regions of tumors, and Nb 11A4 against HER2. This evidence concerns the gene CA9 and neoplasm.